Condition
Chronic Kidney Disease
Locations
Argentina, Japan, Korea, Republic of, Malaysia, Turkey, United States
Start date
02/12/2024
Identifiers
Trial ID
NN9541-7841,
NCT number NCT06717698,
Eudract number Not Available
NCT number NCT06717698,
Eudract number Not Available
Summary
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study will last for up to 43 weeks.
Trial Overview:
Treatment
DRUG: NNC0519-0130
DRUG: Placebo
DRUG: Semaglutide
Study type
INTERVENTIONAL
Trial duration
Dec 02 2024 - Sep 29 2026
Participants
465
Phase
II
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.